PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin
CompletedNCT02273908
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic low back pain patients with accompanying lower limb pain (neuropathic component) treated in primary care settings under routine clinical practice.
Study details
- Official title
- Patient-reported-outcomes(PROs) in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings
- Conditions
- Low-Back Pain
- Interventions
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Organization
- Pfizer
- Start date
- 2014-07
- Primary completion
- 2015-02
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Japan
- Total sites listed
- 33
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Subject who received the enough study information and signed informed consent form. 2. Subject who had chronic low back pain accompanying with lower limb pain from the knee to the ankle. 3. Subject is male or female patient ≥18 years old. 4. Subject who has complained low back pain for 3 months or more before Visit 1. 5. Subject who is refractory to prior analgesics for 3 months and more. 6. Subject who is able and willing to complete all study related assessment and comply with the study schedule and clinical procedures at clinic. 7. Subject whose pain Numeric Rating Scale(NRS) ≥ 5 at baseline (based on recall over the past week) Exclusion Criteria: 1. Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason. 2. Subject who has been already treated by pregabalin
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02273908